• FDA hands out approvals to Takeda transplant drug, Aadi Bio cancer therapy

    13 days ago - By MedCity News

    Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, making it the first therapy authorized for treating a rare type of soft-tissue cancer.
    Read more ...